NCT06224907
Hemophilia A, Hemophilia a
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in Japanese patients with severe hemophilia A.
Male
From 18 Years
Yes
Valoctocogene roxaparvovec
Phase 3
Interventional
6
2023-12-25
2024-05-07
Hokkaido, Asahikawa, Japan
Saitama, Iruma-gun, Japan
Aichi, Nagoya, Japan
Tokyo, Shinjuku-ku, Japan
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields